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Low-dose aspirin and survival from lung
cancer: a population-based cohort study
Úna C. Mc Menamin1*, Chris R. Cardwell1, Carmel M. Hughes2 and Liam M. Murray1,3
Abstract
Background: Preclinical evidence suggests that aspirin may inhibit lung cancer progression. In a large cohort of lung
cancer patients, we investigated whether low-dose aspirin use was associated with a reduction in the risk of lung
cancer-specific mortality.
Methods: We identified lung cancer patients from English cancer registries diagnosed between 1998 to 2009 from the
National Cancer Data Repository. Medication usage was obtained from linkages to the UK Clinical Practice Research
Datalink and lung cancer-specific deaths were identified from Office of National Statistics mortality data. Hazard ratios
(HR) and 95 % confidence intervals (CI) for the association between low-dose aspirin use (before and after diagnosis)
and risk of lung cancer-specific mortality were calculated using Cox regression models.
Results: A total of 14,735 lung cancer patients were identified during the study period. In analysis of 3,635 lung cancer
patients, there was no suggestion of an association between low-dose aspirin use after diagnosis and cancer-specific
mortality (adjusted HR = 0.96, 95 % CI: 0.85, 1.09). Similarly, no association was evident for low-dose aspirin use before
diagnosis and cancer-specific mortality (adjusted HR = 1.00, 95 % CI: 0.95, 1.05). Associations were comparable by duration
of use and for all-cause mortality.
Conclusion: Overall, we found little evidence of a protective association between low-dose aspirin use and
cancer-specific mortality in a large population-based lung cancer cohort.
Keywords: CPRD, Low-dose aspirin, Lung cancer survival, Pharmacoepidemiology
Background
It is increasingly recognised that platelets play a critical
role in the progression of cancer [1–3]. The use of
aspirin, a commonly prescribed anti-platelet agent, after
cancer diagnosis has been associated with a reduction in
the risk of recurrence or cancer-specific mortality in colo-
rectal [4, 5], breast [6, 7] and prostate [8] cancer cohorts.
Partly motivated by these studies, a large phase 3 rando-
mised trial of aspirin as adjunct treatment is soon to com-
mence including patients at these sites [9]. A similar trial
in lung cancer patients was planned but not conducted
[10]. Accruing preclinical data suggest that aspirin may
have anti-cancer properties [11, 12] by suppressing cellu-
lar proliferation [13], reducing neo-vascularisation [14]
and inhibiting cell migration and the formation of
metastases [15, 16]. Few epidemiological studies have
examined the impact of aspirin on the progression of lung
cancer, despite promising in vivo preclinical evidence of
relevance to lung cancer [17, 18] and evidence that lung
cancer patients previously exposed to low-dose aspirin
present with more favourable tumour characteristics [19].
Only one epidemiological study has investigated cancer-
specific outcomes in users of aspirin after lung cancer
diagnosis, a time period when clinical intervention is pos-
sible. In a small cohort of 643 patients diagnosed with
stage III non-small cell lung cancer, Wang et al. [20]
reported a substantial, albeit non-significant reduction in
the risk of distant cancer metastasis in users of aspirin
(but not specifically low-dose) during definitive radiother-
apy. Other studies have investigated aspirin use and over-
all survival but these results could reflect mortality from
non-cancer causes. A cohort study of 1,765 non-small cell
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lung cancer patients reported a significant improvement
in overall survival among those using aspirin (but not
specifically low-dose) pre-operatively [21]. No difference
in the rate of overall survival was observed in patients
assigned to an anti-inflammatory daily dose of 1000 mg
aspirin compared to non-treatment in a small randomised
trial of 303 small cell lung cancer patients [22]. These 3
studies provide limited information as they were not
population-based [20, 21], did not investigate low-dose
aspirin solely and used limited time-points to ascertain
drug exposure. Further epidemiological studies of the
impact of low-dose aspirin use on lung cancer progression
are therefore warranted to inform the conduct of rando-
mised trials of low dose aspirin as adjunct treatment in
lung cancer patients.
In a large population-based cohort of cancer-registry
confirmed lung cancer patients utilising detailed prescrib-
ing records, we aimed to investigate whether low-dose as-
pirin use, either before and after diagnosis, was associated
with a reduced cancer-specific mortality.
Methods
Data sources
This study utilised record linkages between the National
Cancer Data Repository (NCDR), the United Kingdom
(UK) Clinical Practice Research Datalink (CPRD) and the
Office of National Statistics (ONS) death registration data.
The NCDR contains data on cancer patients diagnosed in
England including the date and site of primary cancer
diagnoses, as well as information on cancer treatments
received. The CPRD is the world’s largest computerised
dataset of anonymised longitudinal primary care records
covering approximately 7 % of the United Kingdom popu-
lation. It comprises general practice records of docu-
mented high quality [23, 24] containing demographics,
clinical diagnoses and prescriptions issued. Date and cause
of death was provided by ONS death registrations. The
CPRD group obtained ethical approval from a Multicentre
Research Ethics Committee (MREC) for purely observa-
tional research using data from the database, such as ours.
This study obtained approval from the Independent Scien-
tific Advisory Committee (ISAC) of the CPRD, which is
responsible for reviewing protocols for scientific quality.
Study design
Between 1998 and 2009, all patients newly diagnosed
with primary lung cancer (International Classification of
disease, ICD code C34) were identified from the NCDR.
Patients with a previous NCDR cancer diagnosis were
excluded, with the exception of in situ neoplasms and
non-melanoma skin cancers. Using ONS death registra-
tion data, deaths were obtained up until January 2012
and lung cancer specific deaths were identified using an
underlying cause of death ICD code C34.
Exposure data
General practitioner (GP)-recorded aspirin prescriptions,
according to the British National Formulary [25], were clas-
sified as low if ≤75 mg (0.1 % of prescriptions after diagno-
sis 25 mg, 92.7 % were 75 mg and 7.3 % were >75 mg). The
average quantity of 28 was assumed for approximately 2 %
of prescriptions were quantity was missing or incorrect.
Covariates
Clinical data on tumour histology, and receipt of cancer
treatments including surgery, chemotherapy and radio-
therapy within 6 months after diagnosis was obtained
from the NCDR. Tumour histology was based on cancer
registry recorded International Classification of Diseases
for Oncology codes (3rd Edition). Data on lifestyle factors
including smoking, alcohol and BMI was derived from the
closest GP records within 10 years prior to diagnosis.
Clinical GP-recorded diagnoses were used to determine
comorbidities prior to diagnosis, and comprised those
which were included in a recent adaptation of the
Charlson Comorbidity index [26]. A measure of deprivation
was available from CPRD records based on the 2004 Index
of Multiple Deprivation for England which comprises super
output area (SOA) level measures of multiple deprivation
(based on UK residential postcodes) and is made up of
seven SOA level domain indices [27]. Patients were cate-
gorised into one of 5 quintiles of deprivation with the first
quintile representing the least deprived and the fifth quin-
tile representing the most deprived. Other medications
including statins and beta-blockers, were determined from
GP-prescription records and included in adjusted analyses
due to potential associations with cancer-specific mortality.
Statistical analysis
Statistical analysis for low-dose aspirin use after diagnosis
In the analysis of low-dose aspirin use after diagnosis
(regardless of pre-diagnostic low-dose aspirin use), lung
cancer patients who died in the first year after diagnosis
were excluded (sensitivity analysis was conducted vary-
ing this interval) as it is likely that these patients had
stage IV disease and it seemed unlikely that short term
post-diagnostic drug use would influence such deaths.
Patients were therefore followed up from one year after
diagnosis until death, end of registration with the
general practice, last date of data collection from general
practice or end of ONS follow-up. Time dependent Cox
regression models were used to produce unadjusted and
adjusted hazard ratios (HRs) and 95 % confidence inter-
vals (CIs) for the association between low-dose aspirin
use and lung cancer-specific mortality. Low-dose aspirin
use was treated as time-varying, with users not
considered to be exposed until after a lag of six months
following their initial prescription. Other medications
including statins and beta-blockers were treated in a
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similar manner. The use of a lag is recommended [28]
and was used to exclude prescriptions in the six months
prior to death as these may reflect changes due to end
of life care. Medications may be withdrawn from cancer
patients in whom death is suspected to be imminent and
unlagged time-varying covariate analysis can bias results
due to reverse causality [29]. Dose–response relationships
were investigated by cumulative number of prescriptions
and increasing number of tablets during the exposure
period, and analyses were repeated for all-cause mortality.
Sub-group analyses were carried out by sex, pre-
diagnostic low-dose aspirin use, histology and surgery
within 6 months after diagnosis. Tests for interactions
were performed for each sub-group analysis. Separate
sensitivity analyses were conducted by: increasing the lag
from 6 months to 1 year (thereby excluding prescriptions
in the year prior to death); only excluding those who died
within the first six months after diagnosis (thereby includ-
ing more of the cohort); and additionally adjusting for
smoking, BMI and histological sub-type. A simplified ana-
lysis was conducted assessing the influence of low-dose
aspirin use versus non-use in the first year after lung
cancer diagnosis among patients who survived at least one
year after diagnosis. In order to verify the robustness of
results (i.e. if the findings are similar to the main analysis
it would suggest that our results are robust), the entire
cohort was converted to case–control data to carry out a
nested case–control analysis using conditional logistic
regression. Cases were patients that died due to lung
cancer and were matched on sex, age (in 5 year bands)
and year of diagnosis (in 2 year bands) to five risk-set
controls that lived at least as long after their lung cancer
diagnosis, thereby eliminating immortal time bias [30].
Odds ratios (ORs) and 95 % confidence intervals (CIs)
were produced using conditional logistic regression to
examine the association between low-dose aspirin use and
lung cancer-specific mortality.
Statistical analysis for low-dose aspirin use before diagnosis
In the analyses of low-dose aspirin use before lung
cancer diagnosis, follow-up began from diagnosis until
death or censoring (as described earlier). Patients who
died in the first year after diagnosis were not excluded.
Cox regression models were used to calculate unadjusted
and adjusted HRs and 95 % CIs based upon prescrip-
tions in the year prior to diagnosis, among patients with
at least 1 year of CPRD records prior to diagnosis. To
prevent over-adjustment in the analysis of pre-diagnosis
low-dose aspirin use, adjustments were only made for
potential confounders recorded prior to cancer diagnosis
[31, 32] (statin and beta-blocker use were also based
upon prescriptions in the year prior to diagnosis). Ana-
lyses were conducted by cumulative number of low-dose
aspirin prescriptions and increasing number of tablets
within the exposure period, and repeated for all-cause
mortality. Sub-group analyses were carried out by sex
and sensitivity analyses included additional adjustment
for smoking and BMI prior to diagnosis and extending
the pre-diagnostic exposure period from 2 years to 6
months prior to diagnosis (among patients with at least
2 years of records prior to diagnosis).
Results
Patient cohort
A total of 14,735 lung cancer patients with linked CPRD
data were identified from the NCDR. The analysis of
aspirin use after diagnosis included 3,635 patients after
excluding 11,100 patients with less than 1 year of follow-
up (10,295 of whom had died). The analysis of aspirin
use before diagnosis included 13,433 patients, after
excluding 1,302 patients with less than 1 year of CPRD
records prior to diagnosis. In the analysis of aspirin use
after diagnosis average follow-up was 3 years (maximum
14 years) and in the analysis of aspirin use before diag-
nosis, average follow-up was 1 year (maximum 14 years).
Patient characteristics
Table 1 lists patient characteristics by low-dose aspirin
use. Users of low-dose aspirin either before or after
diagnosis were more likely to be diagnosed more
recently, be older, be male and be overweight or obese
prior to cancer diagnosis. The majority of comorbidities
were also more common in users of aspirin (particu-
larly cerebrovascular disease, diabetes and myocardial
infarction), in addition to the use of statins and beta-
blockers. Low-dose aspirin users after diagnosis were
less likely to undergo chemotherapy. Other patient
characteristics were not as strongly associated with the
use of low-dose aspirin.
Association between low-dose aspirin use after diagnosis
and survival
There was no evidence of an association between low-
dose aspirin use after diagnosis and lung cancer-specific
mortality (HR = 0.96, 95 % CI: 0.87, 1.05), as shown in
Table 2. No dose–response relationship was evident by
increasing prescriptions of low-dose aspirin, or by
tablets. Similarly, no difference in the rate of all-cause
mortality was observed between users of low-dose
aspirin and non-users, Table 2. Adjustment for potential
confounders including cancer treatments and comorbid-
ities did not materially alter risk estimates. In sub-group
analyses, associations between low-dose aspirin use and
cancer-specific mortality did not differ by sex, pre-
diagnostic low-dose aspirin use or surgical treatment,
see Table 3. There was a suggestion of a small, although
not statistically significant, reduction in the risk of
cancer-specific mortality in patients diagnosed with
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Table 1 Characteristics of lung cancer patients by low-dose aspirin use
Characteristics Total study population Low-dose aspirin use in year prior to diagnosisa Low-dose aspirin use after diagnosisb
User n (%) Non-user (%) Ever n (%) Never (%)
(n = 14,735) (n = 13,433) (n = 3,635)
Year of diagnosis: 1998–2000 2,797 (19) 459 (12) 1,850 (19) 175 (15) 463 (19)
2001–2003 3,708 (25) 831 (22) 2,524 (26) 280 (24) 603 (24)
2004–2006 4,025 (27) 1,175 (30) 2,603 (27) 322 (28) 647 (26)
2007–2009 4,205 (29) 1,404 (36) 2,587 (27) 384 (33) 761 (31)
Age at diagnosis: < 50 492 (3) 11 (0) 410 (4) 10 (1) 163 (7)
50–59 1,780 (12) 171 (4) 1,425 (15) 97 (8) 475 (19)
60–69 3,912 (27) 916 (24) 2,660 (28) 362 (31) 804 (33)
70–79 5,347 (36) 1,681 (44) 3,231 (34) 478 (31) 775 (31)
80–89 2,898 (20) 974 (25) 1,677 (18) 199 (17) 242 (10)
≥90 306 (2) 116 (3) 161 (2) 15 (1) 15 (1)
Gender: Males 8,701 (59) 1,581 (63) 6,360 (58) 748 (64) 1,357 (55)
Treatment within 6 months of cancer diagnosis
Surgeryc 1,324 (12) 329 (11) 895 (12) 305 (34) 567 (30)
Chemotherapy 3,287 (22) 709 (18) 2,324 (24) 309 (27) 950 (38)
Radiotherapy 4,668 (32) 1,129 (29) 3,100 (32) 389 (34) 989 (40)
Histology: Non-small cell 8,224 (56) 2,066 (53) 5,478 (57) 822 (71) 1,793 (73)
Small cell 1,828 (12) 458 (12) 1,218 (13) 121 (10) 303 (12)
Missing 4,683 (32) 1,345 (35) 2,868 (30) 218 (19) 378 (15)
Smoking status prior to cancer diagnosis
Non-smoker 1,907 (13) 543 (14) 1,188 (12) 148 (13) 339 (14)
Ex-smoker 5,214 (35) 1,754 (45) 3,111 (33) 541 (47) 852 (34)
Current smoker 5,961 (41) 1,329 (34) 4,138 (43) 393 (34) 1,042 (42)
Missing 1,653 (11) 243 (6) 1,127 (12) 79 (7) 241 (10)
Alcohol consumption prior to diagnosis
Never 2,311 (16) 727 (19) 1,385 (15) 190 (16) 342 (14)
Ever 9,707 (66) 2,678 (69) 6,337 (66) 841 (72) 1,712 (69)
Missing 2,717 (18) 464 (12) 1,842 (19) 130 (11) 420 (17)
BMI (kg/m2) prior to diagnosis: mean (sd)
Underweight (<18.5) 735 (5) 175 (5) 487 (5) 38 (3) 100 (4)
Normal (18.5 to 25) 5,325 (36) 1,379 (36) 3,543 (37) 401 (35) 943 (38)
Overweight (25–30) 3,916 (27) 1,199 (31) 2,444 (26) 388 (33) 695 (28)
Obese (>30) 1,702 (12) 602 (16) 1,002 (11) 196 (17) 287 (12)
Missing 3,057 (21) 514 (13) 2,088 (22) 138 (12) 449 (18)
Deprivation fifth: 1st (least deprived) 2,583 (18) 650 (17) 1,696 (18) 206 (18) 481 (19)
2nd 2,822 (19) 754 (20) 1,833 (19) 236 (20) 451 (18)
3rd 2,975 (20) 778 (20) 1,954 (20) 232 (20) 492 (20)
4th 3,235 (22) 815 (21) 2,102 (22) 250 (22) 556 (23)
5th (most deprived) 3,062 (21) 859 (22) 1,947 (20) 233 (20) 489 (20)
Missing 58 (0) 13 (0) 32 (0) 4 (0) 5 (0)
Comorbidity prior to cancer diagnosis
Cerebrovascular disease 1,.325 (9) 746 (19) 498 (5) 147 (13) 95 (4)
Chronic pulmonary disease 3,619 (25) 1,054 (27) 2,341 (25) 307 (26) 621 (25)
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small cell lung cancer using low-dose aspirin after diag-
nosis (adjusted HR = 0.72, 95 % CI: 0.52, 1.01; P for
interaction = 0.034). Results from sensitivity analyses
were comparable to that of the main analysis, Table 3.
Association between low-dose aspirin use before
diagnosis and survival
Overall, no association between aspirin use prior to diag-
nosis and lung cancer-specific mortality was observed
(adjusted HR = 1.00, 95 % CI: 0.95, 1.05) and no dose–re-
sponse relationship was apparent in analyses by increasing
prescriptions or tablets, Table 4. Similar associations were
observed across sub-group and sensitivity analyses; for
example, after additional adjustment for smoking and
BMI (Table 5).
Discussion
In this population-based study, we did not find evidence
of a protective association between low-dose aspirin use
and cancer-specific or all-cause mortality in a large
cohort of lung cancer patients. Only one previous study
has assessed the impact of aspirin on lung cancer-
specific outcomes. An American study of 643 non-small
cell lung cancer patients conducted by Wang et al. [20]
observed a substantial non-significant decrease in the
risk of distant metastasis in users of aspirin (but not
specifically low-dose) after diagnosis (HR = 0.75, 95 %
CI: 0.55–1.03). Inconsistencies between the findings of
this study and ours could reflect differences in the meth-
odologies employed. Their study was hospital-based,
used a different outcome (distant metastasis), as well as
a different method to ascertain aspirin exposure (based
upon patient recall during the receipt of definitive radio-
therapy). A further study by Fontaine et al. [21], based in
the UK, observed a significant reduction in all-cause
mortality among pre-operative users of aspirin (HR =
0.84, P = 0.05). The authors hypothesised that the
observed benefit in all-cause mortality may be due to an
improvement in cardiovascular-related mortality, as the
reduction in risk was most evident after 3 years [21]. In
contrast, we found no evidence of a protective associ-
ation between low-dose aspirin use and all-cause mortal-
ity. A meta-analysis of randomised controlled trials of
low-dose aspirin (in patients with increased cardiovascu-
lar risk) observed reduced mortality due to lung cancer
but this largely reflected lung cancer incidence as
patients were cancer-free at randomisation [33]. Our
study only investigated low-dose aspirin, hence we
cannot rule out a possible benefit of high-dose cycloxy-
genase (COX)-2 inhibitory aspirin. A previous study,
although relatively small and based on patient report,
did not observe an association between pre-diagnostic
high- or low-dose aspirin and lung cancer survival [34].
Furthermore, our study contained relatively few very
long term low-dose aspirin users (i.e. more than 5 years)
and therefore it is difficult to comment on the effect of
very long term aspirin use.
In sensitivity analyses, we observed a non-significant
28 % reduction in risk of lung cancer-specific mortality
with post-diagnostic aspirin use in patients diagnosed
with small cell lung cancer. Caution however is required
in the interpretation of this finding as this was not an a
priori defined subgroup analysis and was based on sub-
stantially smaller numbers compared to the main ana-
lysis (328 versus 2,247 deaths, respectively).
Our study had a number of strengths and limitations.
This is the first study to evaluate the impact of low-dose
aspirin use and lung cancer-specific mortality. The
cohort was identified from the NCDR, a large population-
based resource which allowed for robust verification of
cancer diagnoses. Similarly, deaths could be confirmed
using ONS. Some misclassification of deaths could have
occurred but evidence from methodological comparative
studies suggest that risk estimates are unlikely to be
Table 1 Characteristics of lung cancer patients by low-dose aspirin use (Continued)
Congestive heart disease 954 (7) 413 (11) 483 (5) 83 (7) 76 (3)
Diabetes 1,552 (11) 758 (20) 698 (7) 194 (17) 141 (6)
Myocardial infarction 1,262 (9) 866 (22) 316 (3) 223 (19) 67 (3)
Peptic ulcer disease 1,087 (7) 264 (7) 745 (8) 65 (6) 182 (7)
Peripheral vascular disease 1,422 (10) 780 (20) 576 (6) 200 (17) 127 (5)
Renal disease 864 (6) 441 (11) 397 (4) 97 (8) 99 (4)
Other medication use after diagnosis
Statin used 4,801 (33) 2,103 (54) 1,193 (13) 705 (61) 410 (17)
Beta-blocker used 3,823 (26) 1,143 (30) 1,005 (11) 416 (36) 272 (11)
aAnalysis includes lung cancer patients who have more than 1 year of records prior to diagnosis
bPost-diagnostic aspirin use (regardless of pre-diagnostic aspirin use), among lung cancer patients who lived more than 1 year after diagnosis
cExcluding cancer patients from Thames Registry as surgery information not available
dStatin and beta-blocker use ever after diagnosis for low-dose aspirin use after diagnosis columns, statins and beta-blocker use in year prior to diagnosis for low-dose
aspirin use in year prior to diagnosis columns, statins and beta-blocker use either before or after diagnosis in total study population column
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Table 2 Association between low-dose aspirin usage after cancer diagnosis and cancer-specific and all-cause mortality in lung cancer patients
Medication usage
after diagnosis
Cancer-specific
deaths
All-cause
mortality
All patients Person years Cancer-specific mortality All-cause mortality
Unadjusted P Adjusteda P Unadjusted P Adjusteda P
HR 95 % CI HR 95 % CI HR 95 % CI HR 95 % CI
Number of patients [n = 3,635] [n = 2,791] [n = 3,635] [n = 2,791]
Aspirin non-user 1,609 1,855 2,474 4,481 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent
Aspirin userb 638 795 1,161 2,264 0.96 0.87, 1.05 0.36 0.96 0.85, 1.09 0.55 1.00 0.92, 1.09 0.92 0.94 0.84, 1.05 0.28
Aspirin non-user 1,609 1,855 2,474 4,481 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent
Aspirin user 1 to 11 prescriptionsc 440 521 670 1,189 0.94 0.85, 1.04 0.25 0.95 0.83, 1.08 0.42 0.97 0.88, 1.07 0.60 0.93 0.83, 1.05 0.24
Aspirin user ≥ 12 prescriptionsc 198 274 491 1,075 1.00 0.86, 1.17 0.96 1.01 0.84, 1.23 0.89 1.07 0.94, 1.23 0.29 0.97 0.82, 1.14 0.69
Aspirin non-user 1,609 1,855 2,474 4,481 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent
Aspirin user 1–365 tabletsc 353 422 541 926 0.91 0.81, 1.02 0.12 0.92 0.80, 1.06 0.27 0.96 0.86, 1.07 0.44 0.92 0.81, 1.05 0.21
Aspirin user ≥366 tabletsc 285 373 620 1,338 1.03 0.90, 1.17 0.69 1.04 0.88, 1.23 0.67 1.07 0.95, 1.20 0.28 0.97 0.84, 1.13 0.72
aAdjusted for year of diagnosis, age at diagnosis, gender, radiotherapy within 6 months, chemotherapy within 6 months, surgery within 6 months, comorbidities (prior to diagnosis, including cerebrovascular disease,
chronic pulmonary disease, congestive heart disease, diabetes, myocardial infarction, peptic ulcer disease, peripheral vascular disease, renal disease), other medication use (after diagnosis, as time varying covariates,
specifically statins and beta-blockers) and deprivation (in fifths)
bMedication use modelled as a time varying covariate with an individual considered a non-user prior to 6 months after first medication usage and a user after this time, excludes deaths in the year after
cancer diagnosis
cMedication use modelled as a time varying covariate with an individual considered a non-user prior to 6 months after first medication usage, a user of 0 to 12 prescriptions from 6 months after first prescription to 6
months after 12th prescription (or 365 tablets) and a greater user after this time, excludes deaths in the year after cancer diagnosis
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Table 3 Sensitivity analyses for association between low-dose aspirin use and cancer-specific mortality in lung cancer patients
Cancer-specific
deaths
All patients Person years User versus non-user User versus non-user
Unadjusted P Adjusted HRa P P for interaction
HRa 95 % CI HRa 95 % CI
Main analysis: Aspirin user versus non-user after diagnosis 2,247 3,635 6,745 0.96 0.87, 1.05 0.36 0.96 0.85, 1.09 0.55
Sub group analyses: Aspirin user versus non-user after diagnosis, restricted to:
Males 1,312 2,105 3,750 1.00 0.89, 1.12 0.97 1.05 0.90, 1.22 0.54 0.12
Females 935 1,530 2,995 0.87 0.75, 1.02 0.08 0.81 0.66, 0.99 0.05
Pre-diagnosis aspirin non-usersb 1,515 2,446 4,578 0.89 0.74, 1.07 0.21 0.91 0.73, 1.14 0.42 0.48
Pre-diagnosis aspirin usersb 554 908 1,601 0.92 0.72, 1.16 0.47 1.02 0.77, 1.35 0.90
Small cell lung cancer 328 424 592 0.84 0.66, 1.09 0.19 0.72 0.52, 1.01 0.05 0.03
Non-small cell lung cancer 1,523 2,615 5,355 0.95 0.85, 1.06 0.35 1.00 0.86, 1.16 0.99
Surgically treated 305 872 2,714 0.99 0.78, 1.27 0.96 0.95 0.71,1.28 0.74 0.39
Non-surgically treated 820 1,708 4,216 0.94 0.80, 1.10 0.42 0.89 0.74, 1.07 0.22
Sensitivity analyses: Aspirin user versus non-user after diagnosis
Increasing lag to 1 year 2,247 3,635 6,745 0.97 0.88, 1.07 0.56 0.97 0.85, 1.10 0.60
Excluding patients who died within the first 6 months after diagnosis 4,440 6,158 9,101 0.96 0.90, 1.03 0.28 0.95 0.87–1.04 0.30
Additionally adjusting for smoking prior to diagnosis 2037 3,315 6,074 0.95 0.86, 1.04 0.28 0.95 0.84, 1.08 0.41
Additionally adjusting for BMI prior to diagnosis 1,849 3,048 5,640 0.93 0.84, 1.03 0.15 0.95 0.84, 1.09 0.47
Additionally adjusting for small cell/non-small cell 1,851 3,039 5,947 0.92 0.83, 1.03 0.14 0.92 0.80, 1.05 0.23
Based upon first year after diagnosisc 1,728 2,791 5,223 0.93 0.87, 1.05 0.33 0.99 0.88, 1.13 0.91
Nested case–control analysisd,e 2,247 0.93 0.85, 1.03 0.19 1.00 0.86, 1.16 0.97
aExcept where otherwise stated, all analyses of post-diagnostic aspirin use adjusted for year of diagnosis, age at diagnosis, gender, surgery within 6 months of diagnosis, radiotherapy within 6 months, chemotherapy within 6 months,
comorbidities (prior to diagnosis, including cerebrovascular disease, chronic pulmonary disease, congestive heart disease, diabetes, myocardial infarction, peptic ulcer disease, peripheral vascular disease, renal disease), other
medication use (after diagnosis, as time varying covariates, specifically statins and beta-blockers) and deprivation (in fifths)
bBased upon aspirin use in the year prior to diagnosis, restricted to individuals with 1 year of records prior to lung cancer diagnosis
cSimplified analysis, not requiring time varying covariate use, comparing aspirin users to aspirin non-users in the first year after diagnosis in individuals living more than 1 year after cancer diagnosis, adjusted for all
confounders ina but other medication use also restricted to first year after diagnosis
dUnadjusted OR estimate and 95 % CIs based on 28 % (623/2,247) of cancer-specific deaths using aspirin compared with 31 % (3,254/10,603) of risk-set controls (not dying from cancer)
eAdjusted OR estimate and 95%CIs, matched on age at diagnosis, year of diagnosis, gender and adjusted for all other confounders ina
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Table 4 Association between low-dose aspirin usage in the year prior to diagnosis and cancer-specific and all-cause mortality in lung cancer patients
Medication usage after diagnosis Cancer-specific
deaths
All-cause
mortality
All patients Person years Cancer-specific mortality All-cause mortality
Unadjusted P Adjusteda P Unadjusted P Adjusteda P
HR 95 % CI HR 95 % CI HR 95 % CI HR 95 % CI
Number of patients [n = 13,433] [n = 13,388] [n = 13,433] [n = 13,388]
Aspirin non-user 7,577 8,369 9,564 9,154 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent
Aspirin user 3,055 3,468 3,869 3,331 1.07 1.02, 1.11 <0.01 1.00 0.95, 1.05 0.91 1.10 1.05, 1.14 <0.001 1.01 0.96, 1.06 0.77
Aspirin non-user 7,577 8,369 9,564 9,154 1.00 Referent 1.00 Referent 1.00 1.00 1.00 Referent
Aspirin user 1 to 11 prescriptions 2,367 2,690 2,998 2,608 1.06 1.01, 1.11 0.02 0.99 0.94, 1.04 0.75 1.09 1.04, 1.14 <0.001 1.00 0.95, 1.05 0.90
Aspirin user ≥ 12 prescriptions 688 778 871 723 1.09 1.01, 1.18 0.03 1.02 0.94, 1.11 0.64 1.11 1.04, 1.20 <0.01 1.02 0.95, 1.11 0.57
Aspirin non-user 7,577 8,369 9,564 9,154 1.00 Referent 1.00 Referent 1.00 1.00 1.00 Referent
Aspirin user 1–365 tablets 2,214 2,508 2,804 2,436 1.06 1.01, 1.12 0.01 1.00 0.95, 1.06 0.97 1.09 1.04, 1.14 <0.001 1.01 0.96, 1.06 0.70
Aspirin user ≥366 tablets 841 960 1,065 895 1.07 1.00, 1.15 0.06 0.98 0.91, 1.06 0.70 1.11 1.04, 1.18 <0.01 1.00 0.93, 1.07 0.97
aAdjusted for year of diagnosis, age at diagnosis, gender, comorbidities (prior to diagnosis, including cerebrovascular disease, chronic pulmonary disease, congestive heart disease, diabetes, myocardial infarction, peptic
ulcer disease, peripheral vascular disease, renal disease), other medication use (in year prior to diagnosis, specifically statins and beta-blockers) and deprivation (in fifths)
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greatly affected [35]. The use of high-quality [22] GP-
recorded prescriptions allowed for detailed investigation
of temporal associations and eliminates potential for recall
bias. Over-the-counter usage of low-dose aspirin is
possible but previous investigation within the General
Practice Research Database found that the majority of
chronic aspirin use was captured by prescription records
[36]. Furthermore, valid treatment risk estimates have
been previously demonstrated when there is potential for
over-the-counter medication usage [37]. Drug compliance
was unknown in this study but similar results were pro-
duced in analysis of multiple prescriptions, in which drug
adherence may be more likely. Although we adjusted for a
range of potential confounding factors, residual confound-
ing caused by unrecorded or incomplete data cannot be
ruled out. More specifically, we were unable to adjust for
cancer stage in our analyses; however, as stage may lie on
the causal pathway, such adjustments may not be appro-
priate for the analysis of low-dose aspirin use before diag-
nosis. Finally, although follow-up time after diagnosis was
up to 14 years in both analysis of post-diagnostic and pre-
diagnostic low-dose aspirin use, the average follow-up
time in each analysis was substantially shorter reflecting
poor survival after lung cancer diagnosis (3 years and 1
year, respectively).
Conclusions
In this population-based study, low-dose aspirin use
was not associated with an improvement in cancer
survival in a large cohort of cancer-registry confirmed
lung cancer patients.
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